Survival benefit of chemotherapy in metastatic colorectal cancer: a meta-analysis of randomized controlled trials
2000
Chemotherapy Improves Survival in Advanced Colorectal Cancer
Sample size: 614
publication
Evidence: high
Author Information
Author(s): Jonker D J, Maroun J A, Kocha W
Primary Institution: Ottawa Regional Cancer Centre and London Regional Cancer Centre
Hypothesis
Does chemotherapy prolong survival in patients with metastatic colorectal cancer?
Conclusion
Chemotherapy significantly prolongs 1-year survival for patients with metastatic colorectal cancer.
Supporting Evidence
- Seven trials with 614 patients were included in the analysis.
- All trials used fluoropyrimidine-based chemotherapy.
- Chemotherapy significantly reduced 1-year mortality.
- The mortality at 2 years was not significantly different.
Takeaway
Chemotherapy helps people with advanced colorectal cancer live longer, especially if they are in good health.
Methodology
A meta-analysis of randomized controlled trials comparing chemotherapy with observation or supportive care was performed.
Participant Demographics
Patients with metastatic colorectal cancer.
Statistical Information
P-Value
P< 0.00001
Confidence Interval
95% CI 0.60–0.81
Statistical Significance
p<0.00001
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website